Healthcare [ 4/11 ] | Health Information Services [ 26/112 ]
US | NASDAQ | Stock
Reported Date | EPSChange YoY | EstimateSurprise |
---|---|---|
Nov 14, 22 | -0.21 | -0.12 Decreased by -625.00% |
Aug 15, 22 | -0.49 | -0.11 Decreased by -3.14 K% |
Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
---|---|---|---|
Dec 31, 22 | 22.52 K Increased by +88.03% | -1.33 M Increased by +59.77% | Decreased by -5.91 K% Increased by +78.61% |
Sep 30, 22 | 18.22 K Increased by +82.73% | -1.63 M Decreased by -221.72% | Decreased by -8.96 K% Decreased by -76.06% |
Jun 30, 22 | 10.68 K - | -5.05 M - | Decreased by -47.30 K% - |
Mar 31, 22 | 9.03 K - | -1.10 M - | Decreased by -12.18 K% - |
Dec 31, 21 | 11.98 K - | -3.31 M - | Decreased by -27.61 K% - |
Dec 31, 20 | 9.97 K - | -507.52 K - | Decreased by -5.09 K% - |
Aclarion, Inc., a healthcare technology company, develops software application for magnetic resonance spectroscopy (MRS) in the United States. It offers NOCISCAN-LS Post-Processor suite comprising NOCICALC-LS that receives and processes the acquired disc MRS data to calculate levels of degenerative pain biomarkers; and NOCIGRAM-LS, a clinical decision support software. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was founded in 2008 and is based in San Mateo, California.